Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg

Next Previous
Trial Profile

Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Embolism; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MIND MRI; NAVIGATE ESUS
  • Sponsors Bayer

Most Recent Events

  • 25 Oct 2021 Results of subgroup analysis determining determine whether anticoagulation is superior to aspirin in reducing recurrent stroke in patients with ESUS and LV dysfunction published in the JAMA Neurology
  • 20 Sep 2021 Results (n=918) of MIND MRI sub-study assessing frequency and pattern of brain infarcts detected by magnetic resonance imaging among patients published in the Stroke
  • 19 Oct 2020 Results of subgroup analysis characterizing microbleeds in embolic strokes of undetermined source (ESUS) and reporting interactions between microbleeds and the effects of random assignment to anticoagulant vs antiplatelet therapy published in the JAMA Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top